These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Pharm Res; 2001 Mar; 18(3):352-60. PubMed ID: 11442276 [Abstract] [Full Text] [Related]
5. Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers. Gupta RK, Alroy J, Alonso MJ, Langer R, Siber GR. Vaccine; 1997 Nov; 15(16):1716-23. PubMed ID: 9364673 [Abstract] [Full Text] [Related]
6. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. Sánchez A, Villamayor B, Guo Y, McIver J, Alonso MJ. Int J Pharm; 1999 Aug 20; 185(2):255-66. PubMed ID: 10460920 [Abstract] [Full Text] [Related]
7. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A, Vyas SP. Int J Pharm; 2005 Apr 27; 294(1-2):23-32. PubMed ID: 15814228 [Abstract] [Full Text] [Related]
8. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. Johansen P, Tamber H, Merkle HP, Gander B. Eur J Pharm Biopharm; 1999 May 27; 47(3):193-201. PubMed ID: 10382103 [Abstract] [Full Text] [Related]
9. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR. Vaccine; 1996 Oct 27; 14(15):1412-6. PubMed ID: 8994315 [Abstract] [Full Text] [Related]
10. Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Sasiak AB, Bolgiano B, Crane DT, Hockley DJ, Corbel MJ, Sesardic D. Vaccine; 2000 Nov 22; 19(7-8):694-705. PubMed ID: 11115690 [Abstract] [Full Text] [Related]
16. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Tobío M, Nolley J, Guo Y, McIver J, Alonso MJ. Pharm Res; 1999 May 22; 16(5):682-8. PubMed ID: 10350011 [Abstract] [Full Text] [Related]
18. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT. Infect Immun; 1997 May 22; 65(5):1716-21. PubMed ID: 9125552 [Abstract] [Full Text] [Related]
20. Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern. Johansen P, Corradin G, Merkle HP, Gander B. J Control Release; 1998 Dec 04; 56(1-3):209-17. PubMed ID: 9801444 [Abstract] [Full Text] [Related] Page: [Next] [New Search]